Renal steatosis is a potential biomarker for obesity-related renal disease and this has been suggested as underlying biological pathway of renoprotective effects of Liraglutide in type 2 diabetes (T2DM). Proton magnetic resonance spectroscopy (¹H-MRS) has the ability to non-invasively quantify triglycerides. We examined the reproducibility of ¹H-MRS in healthy volunteers, and explored the application in a clinical trial evaluating the differences in renal triglyceride content after 9-month treatment with liraglutide. We demonstrated that ¹H-MRS is a reproducible technique and comparison with healthy volunteers suggests increased renal triglycerides in T2DM. Renoprotective effects of liraglutide might be based on reduced renal triglycerides.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords